Genetic Counseling or Usual Care in Helping Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I, Stage II, or Stage IIIA Breast Cancer Make Treatment Decisions - Full Text View

Purpose

RATIONALE: Genetics education and counseling may help patients make treatment decisions. It is not yet known how genetic counseling or usual care influence patient treatment decisions for breast cancer.

PURPOSE: This randomized clinical trial is studying how well genetic counseling works compared to usual care in helping patients with newly diagnosed ductal carcinoma in situ, stage I, stage II, or stage IIIA breast cancer make treatment decisions.

Condition	Intervention	Phase
Breast Cancer Psychosocial Effects of Cancer and Its Treatment	Behavioral: counseling intervention Other: educational intervention Procedure: psychosocial assessment and care	Phase 3


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Prevention
Official Title:	Genetic Counseling for Newly Diagnosed Breast Cancer Patients

Resource links provided by NLM:

Genetics Home Reference related topics: breast cancer

MedlinePlus related topics: Breast Cancer Genetic Counseling

U.S. FDA Resources

Further study details as provided by Marc D Schwartz, Georgetown University:

Primary Outcome Measures:

Definitive surgery choice as measured by self-reported and medical record verification at 6 months after randomization [ Time Frame: 1, 6, and 12 months ]
Quality of life as measured by functional assessment of cancer therapy for breast cancer (FACT-B) at 1, 6, and 12 months after randomization [ Time Frame: 1, 6, and 12 months ]
Distress as measured by Impact of Events Scale Brief Symptom Inventory at 1, 6, and 12 months after randomization [ Time Frame: 1, 6, and 12 months ]
Knowledge as assessed by Genetic Testing Knowledge Measure at 1 month after randomization [ Time Frame: 1 month ]
Decision outcomes as assessed by Decisional Conflict Scale Satisfaction with Decision Scale at 1 and 6 months after randomization [ Time Frame: 1 and 6 months ]

Secondary Outcome Measures:

Cost effectiveness as measured by quality adjusted life years saved at 12 months after randomization [ Time Frame: 12 months ]


Enrollment:	331
Study Start Date:	August 2005
Study Completion Date:	July 2011
Primary Completion Date:	July 2010 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Rapid genetic counseling Following randomization, participants will be informed about whether they are assigned to Usual Care (UC) or Rapid Genetic Counseling (RGC). Participants in the UC arm can schedule a genetic counseling appointment at any time during the study if they wish. Participants in the RGC agree to obtain genetic counseling as soon as possible, before they make a definitive surgery decision. RGC can be accomplished by telephone or in-person. The RGC intervention is delivered by highly experienced genetic counselors at each site. This counseling is identical to our standard genetic counseling procedure for newly diagnosed patients. Immediate DNA collection via blood or buccal cell collection is available following counseling. Phone counseling participants will be been mailed a kit for DNA collection or have the option of having the sample collected at at LCCC.	Behavioral: counseling intervention Other: educational intervention Procedure: psychosocial assessment and care
No Intervention: Usual Care Usual Care (UC) for newly diagnosed breast cancer patients does not typically include a pre-surgical genetic referral. These patients may obtain genetic counseling at their own discretion.

Arms

Assigned Interventions

Experimental: Rapid genetic counseling

Following randomization, participants will be informed about whether they are assigned to Usual Care (UC) or Rapid Genetic Counseling (RGC). Participants in the UC arm can schedule a genetic counseling appointment at any time during the study if they wish. Participants in the RGC agree to obtain genetic counseling as soon as possible, before they make a definitive surgery decision. RGC can be accomplished by telephone or in-person. The RGC intervention is delivered by highly experienced genetic counselors at each site. This counseling is identical to our standard genetic counseling procedure for newly diagnosed patients. Immediate DNA collection via blood or buccal cell collection is available following counseling. Phone counseling participants will be been mailed a kit for DNA collection or have the option of having the sample collected at at LCCC.

Behavioral: counseling intervention Other: educational intervention Procedure: psychosocial assessment and care

No Intervention: Usual Care

Usual Care (UC) for newly diagnosed breast cancer patients does not typically include a pre-surgical genetic referral. These patients may obtain genetic counseling at their own discretion.

Detailed Description:

OBJECTIVES:

Compare the impact of rapid genetic counseling (RGC) vs usual care on the medical decisions of women with newly diagnosed ductal carcinoma in situ or stage I-IIIA breast cancer.
Compare the impact of these interventions on the quality of life and psychological well being of these patients.
Determine baseline factors that predict who is most and least likely to benefit from RGC in patients undergoing these interventions.
Compare the cost per quality adjusted life year saved from a societal perspective in patients undergoing these interventions.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to participating site. Patients are randomized to 1 of 2 interventional arms.

Arm I (rapid genetic counseling): Patients undergo a 1½ hour genetic counseling session either in person or by telephone. Patients who undergo telephone counseling receive a booklet of visual aids and educational materials. Patient preferences and values are assessed immediately after counseling. Some patients may undergo BRCA1/2 status determination. Patients undergo follow-up telephone interviews at 1, 6, and 12 months.
Arm II (usual care): Patients receive a packet of breast cancer treatment educational materials. Patient preferences and values are assessed 2 weeks later. Patients undergo follow-up telephone interviews as in arm I.

In both arms, quality of life is assessed at baseline and at 1, 6, and 12 months.

After completion of the study, patients are followed periodically for 1 year.

PROJECTED ACCRUAL: A total of 360 patients will be accrued for this study.

Eligibility


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Sexes Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

DISEASE CHARACTERISTICS:

Newly diagnosed breast cancer, meeting 1 of the following criteria:
- Stage 0 disease (ductal carcinoma in situ only)
- Stage I-IIIA disease
Must meet 1 of the following criteria:
- Diagnosis before 50 years of age
- Diagnosis after 50 years of age AND has 1 of the following:
  - First or second degree relative diagnosed with breast cancer before 50 years of age
  - First or second degree relative diagnosed with ovarian cancer at any age
  - First or second degree relative diagnosed with male breast cancer at any age
Must not have initiated definitive treatment for breast cancer
No bilateral, metastatic, or inflammatory breast cancer
No prior BRCA1/2 counseling or testing
No prior diagnosis of metastatic cancer of any type
Hormone receptor status:
- Not specified

PATIENT CHARACTERISTICS:

Sex

Female

Menopausal status

Not specified

Performance status

Not specified

Life expectancy

Not specified

Hematopoietic

Not specified

Hepatic

Not specified

Renal

Not specified

PRIOR CONCURRENT THERAPY:

Surgery

No prior bilateral mastectomy for breast cancer

Other

No concurrent treatment for cancer

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00262899

Locations


United States, District of Columbia
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
Washington, District of Columbia, United States, 20007
United States, Maryland

Chevy Chase, Maryland, United States, 20815
United States, New Jersey
Hackensack University Medical Center Cancer Center
Hackensack, New Jersey, United States, 07601
United States, New York
Mount Sinai School of Medicine
New York, New York, United States, 10029

Sponsors and Collaborators

Georgetown University

National Cancer Institute (NCI)

Investigators


Study Chair:	Marc Schwartz, PhD	Lombardi Comprehensive Cancer Center

More Information


Responsible Party:	Marc D Schwartz, Professor of Oncology, Georgetown University
ClinicalTrials.gov Identifier:	NCT00262899 History of Changes
Other Study ID Numbers:	CDR0000450155 R01CA108933 ( US NIH Grant/Contract Award Number ) R01CA074861 ( US NIH Grant/Contract Award Number ) P30CA051008 ( US NIH Grant/Contract Award Number ) GUMC-2004-212
Study First Received:	December 6, 2005
Last Updated:	January 4, 2013

Keywords provided by Marc D Schwartz, Georgetown University:


psychosocial effects of cancer and its treatment ductal breast carcinoma in situ breast cancer in situ stage IA breast cancer	stage IB breast cancer stage II breast cancer stage IIIA breast cancer

Additional relevant MeSH terms:


Breast Neoplasms Carcinoma in Situ Neoplasms by Site Neoplasms Breast Diseases	Skin Diseases Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type

ClinicalTrials.gov processed this record on June 23, 2017